Hyper Terminal logo
Company earnings

FTH Earnings Date & History

Faeth Therapeutics, Inc (NASDAQ NMS - GLOBAL MARKET) earnings schedule, consensus estimates and reported results for the last eight quarters.

Last updated Oct 28, 2026 at 6:39 PM ET

Faeth Therapeutics, Inc

Biotechnology

Next earnings date
Tuesday, November 10, 2026
Reporting session
Time TBD
EPS estimate
$-0.80
Revenue estimate
$0

Research beyond the earnings headline

What’s happening around FTH?

Congressional Trading

Review purchases and sales when available, transaction and disclosure dates kept separate

Members-only details

Previews show an example layout only, not data for FTH. Coverage varies by company.

FTH earnings history

Report dateQuarterEPS est.EPS actualSurpriseRevenue
Tuesday, August 4, 2026Q2 2026$-3.08$-2.84+7.7%$0
Friday, May 15, 2026Q1 2026$-0.63$-28.79-4497.6%$0
Monday, March 30, 2026Q4 2025$-4.86$-3.74+23.0%$0
Friday, November 14, 2025Q3 2025$-4.15$-3.62+12.8%$0

What the market is watching in FTH's next report

  • The full Earnings Read for this company: focus areas, peer read-through and prior-reaction context.
  • Ticker Read combines trend, relative strength and catalysts in one research view.
  • Scanners, daily catalyst context and the members-only Weekly Watchlist are included.
Free by email

Get the week's earnings by email

One free email each week: the reports that matter, when they land, and what the market is watching.

No account required. Unsubscribe any time. Research and education only, not investment advice.

Frequently asked questions

Calendar data is provided for educational and research purposes only and is not investment advice. Release dates, times, estimates and results can change; always verify against the issuing company or agency.

FTH earnings discussion

Anyone can read. Any free Hyper Stocks account can join in.

Create a free account to join the discussion. Reading is open to everyone, commenting is free, no subscription needed.

Loading discussion…

Member comments are opinions from individual users, not Hyper Stocks research, and are never personalised investment advice.